LC
CRMD icon

Lindbrook Capital’s CorMedix CRMD Stock Holding History

Lindbrook Capital’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$499 Hold
81
– – ﹤0.01% 2618
2024
Q4 		$656 Hold
81
– – ﹤0.01% 2563
2024
Q3 		$654 Buy
+81
New +$438 ﹤0.01% 2598

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Lindbrook Capital's CRMD Position: Q1 2025 in Review

Lindbrook Capital held its CorMedix (CRMD) position steady in Q1 2025 at 81 shares worth $499. The position accounts for ﹤0.01% of the portfolio, ranked #2618.

Lindbrook Capital first reported a position in CRMD in Q3 2024 and has held it in 3 quarters since. The position peaked at $656 in Q4 2024. 137 funds tracked by Wall St. Rank hold CRMD as of Q1 2025.

  • Lindbrook Capital held 81 shares of CorMedix worth $499 as of Q1 2025.
  • Lindbrook Capital left its CorMedix share count unchanged in Q1 2025.
  • CorMedix made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2618 holding.
  • Lindbrook Capital first reported a position in CorMedix in Q3 2024 and has held it in 3 quarters since.
  • Lindbrook Capital's CorMedix position peaked at $656 in Q4 2024.
  • 137 funds tracked by Wall St. Rank held CorMedix as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.